Heilongjiang Tianlong Pharmaceutical, Inc. (''Tianlong''), a wholly-owned
subsidiary of China Sky One Medical, Inc., recently completed research and
development for the spray, which includes the active ingredients Naphazoline
Hydrochloride Chlorpheniramine Maleate and Benzalkonium Bromide. Rheumatic
diseases are shown in common sympathies and characterized by joint
inflammation. There are currently only five other manufacturers of the spray
in China and
''We are very excited about the development of this spray, which serves a
huge market in China,'' said Mr.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a
Safe Harbor Statement
Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by the use
of forward- looking terminology such as "believe," "expect," "may," "will,"
"should," "project," "plan," "seek," "intend," or "anticipate" or the negative
thereof or comparable terminology. Such statements typically involve risks and
uncertainties and may include financial projections or information regarding
our future plans, objectives or performance. Actual results could differ
materially from the expectations reflected in such forward-looking statements
as a result of a variety of factors, including the risks associated with the
effect of changing economic conditions in
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Yu-Bo Hao, Board Secretary
Tel: +86-451-5399-4069
Email: china_sky_one@yahoo.cn
Investor Relations Contact:
CCG Investor Relations
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Mr. Richard Micchelli
Financial Writer
Tel: +1-646-454-4516
Email: richard.micchelli@ccgir.com
Web: http://www.ccgir.com
SOURCE China Sky One Medical, Inc.